0000000000012867
AUTHOR
M Climente Martí
showing 5 related works from this author
Calidad de la farmacoterapia y seguridad de los pacientes en hemodiálisis tratados con estimulantes eritropoyéticos
2008
Objective: To assess an interdisciplinary programme for the improvement of pharmacotherapy quality and patient safety in patients with chronic renal disease who are treated with erythropoiesis-stimulating agents. Method: Observational, longitudinal study. Retrospective analysis (period A) and prospective analysis (period B) following implementation of the programme for haemoglobin values and monthly erythropoiesis- stimulating agent dosage. The proportion of patients with haemoglobin values within the target range (10-5-12.5 g/dl) and those with values above the safety limit (≥ 12.5g/dl) were compared every four months and the average percentage of time with haemoglobin values within the ta…
Evaluación de la calidad de dos modelos de atención farmacéutica en pacientes onco-hematológicos
2007
Objective: To compare the quality of two pharmaceutical care models (with and without pharmacist participation in the clinical team), in hospitalised onco-haematological patients. Method: A prospective cohort study in the oncology and haematology departments of a university hospital over a 26-month period. A centralised model (model C) was used over 16 months and a decentralised integration model (model D) was used during the remaining 10 months. The Iaser© methodology was used to identify candidates for improved drug treatment and for the follow up of patients with drug-related problems (DRP). The results obtained were compared using a series of pharmaceutical care quality indicators. Resu…
Development and application to clinical practice of a validated HPLC method for the analysis of β-glucocerebrosidase in Gaucher disease.
2014
The main objective of our study is to develop a simple, fast and reliable method for measuring ß-glucocerebrosidase activity in Gaucher patients leukocytes in clinical practice. This measurement may be a useful marker to drive dose selection and early clinical decision making of enzyme replacement therapy. We measure the enzyme activity by high-performance liquid chromatography with ultraviolet detection and 4-nitrophenyl-ß-d-glucopyranoside as substrate. A cohort of eight Gaucher patients treated with enzyme replacement therapy and ten healthy controls were tested; median enzyme activity values was 20.57mU/ml (interquartile range 19.92-21.53mU/ml) in patients and mean was 24.73mU/ml (24.12…
Doctors’ acceptance of recommendations for patients with the opportunity for pharmacotherapy improvement
2011
Abstract Objective To identify and quantify the influence of different variables on the implementation of pharmacotherapy optimisation measures in hospitalised patients. Method Descriptive transversal study. Period: 2000–2007. Environment: public university general hospital (25,000 patients admitted/year). The Programme implemented to improve pharmacotherapy quality and patient safety covers 30% of all patients. Using records from the Atefarm ® Farmis application, we analysed pharmacotherapy recommendations (PRs) made by pharmacists to doctors. The selected variables were the following: Risk of the medication for ADE (1-high, 0-low), ADE category, (0-indication, 1-effectiveness, 2-safety), …
Pharmacotherapy quality and patient safety in haemodialysis patients treated with erythropoiesis-stimulating agents
2008
Abstract Objective To assess an interdisciplinary programme for the improvement of pharmacotherapy quality and patient safety in patients with chronic renal disease who are treated with erythropoiesisstimulating agents. Method Observational, longitudinal study. Retrospective analysis (period A) and prospective analysis (period B) following implementation of the programme for haemoglobin values and monthly erythropoiesisstimulating agent dosage. The proportion of patients with haemoglobin values within the target range (10-5-12.5 g/dL) and those with values above the safety limit (≥12.5 g/dL) were compared every 4 months and the average percentage of time with haemoglobin values within the t…